| Project/Area Number |
15K19701
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 悪性黒色腫 / BCL2 / paclitaxel / 分子標的治療薬 / チューブリン / アブラキサン / チューブリン阻害薬 / 薬剤耐性 / ABT737 |
|---|
| Outline of Final Research Achievements |
Malignant melanoma is refractory to antitubulin agents. Treatment of the paclitaxel-resistant cell lines combined paclitaxel protein-bound particles for injectable suspension with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells' sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect. Our results demonstrated the new combination therapy for malignant melanomas.
|
